Sakakibara Shan Riku
Known title: Chief Product OfficerCIK: 0002088547
Associated companies
Transaction History
| BLLN | ▼ Sell | Gift | 3,500 | $0 | 9/10/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 4,000 | $561K | 7/31/2026 | View on chart |
| BLLN | ▲ Buy | Option Exercise | 174 | $2K | 7/9/2026 | View on chart |
| BLLN | ▲ Buy | Option Exercise | 1,117 | $34K | 7/9/2026 | View on chart |
| BLLN | ▲ Buy | Option Exercise | 1,355 | $42K | 7/9/2026 | View on chart |
| BLLN | ▲ Buy | Option Exercise | 1,354 | $42K | 7/9/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 4,000 | $500K | 7/9/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 174 | $22K | 7/9/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,355 | $169K | 7/9/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,354 | $169K | 7/9/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,117 | $140K | 7/9/2026 | View on chart |
| BLLN | ▲ Buy | Option Exercise | 4,000 | $35K | 6/24/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 4,000 | $440K | 6/24/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 4,000 | $440K | 6/24/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 4,000 | $386K | 6/8/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 4,000 | $400K | 6/8/2026 | View on chart |
| BLLN | ▼ Sell | Other | 220,000 | — | 11/7/2025 | View on chart |
| BLLN | ▼ Sell | Other | 220,000 | — | 11/7/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLLN Gets Price Target Hike and New Study Data
BillionToOne reported that its Northstar Response test showed results comparable to or better than tumor-informed assays in a new peer-reviewed study. Guggenheim raised its price target to $128, while other analysts noted rising reimbursement risks. The stock is currently trading near its support level of $95.81.
BLLN Gets Price Target Hike and New Study Data. BillionToOne reported that its Northstar Response test showed results comparable to or better than tumor-informed assays in a new peer-reviewed study. Guggenheim raised its price target to $128, while other analysts noted rising reimbursement risks. The stock is currently trading near its support level of $95.81.